US Stock Market Movement: Alamar Biosciences surges on October 5th driven by Alzheimer’s, performance growth, and proteomics

Alamar Biosciences October 5 Surge Interpretation

Keywords: Alzheimer, performance growth, proteomics

1. On September 24, a longitudinal cohort study on Alzheimer's disease supported by the company's technology was published in The Lancet Neurology. The study used NULISAseq™ CNS 120 to detect 130 types of plasma proteins and analyzed 2,385 samples from 1,967 participants, showing differences in proteins related to amyloid protein clearance and cognitive decline.

2. On August 10, the company reported second quarter 2026 revenue of $29.4 million, up 82% year-on-year; consumables revenue was $15.5 million, up 147% year-on-year; gross margin reached 60%, and full-year 2026 revenue is expected to be $116 million to $120 million, with the midpoint representing a 59% year-on-year increase.

3. On August 10, the company expanded its strategic cooperation with the Alzheimer's Disease Data Initiative and Gates Ventures, adding 86,000 plasma sample analyses, with the combined dataset expected to exceed 140,000 samples; meanwhile, it launched NULISAseq™ Neuro 220 and Immune 340 Panel to expand research applications in neurological diseases and immunity.

(Disclaimer: This content is collected and summarized from public information by AI technology, and is for reference only. It does not constitute investment advice.)